* Nurix Therapeutics Inc NRIX.OQ reported a quarterly
adjusted
loss of 71 cents per share for the quarter ended in May, lower
than the same quarter last year, when the company reported EPS
of -45 cents. The mean expectation of twelve analysts for the
quarter was for a loss of 63 cents per share. Wall Street
expected results to range from -85 cents to -40 cents per share.
* Revenue fell 60.6% to $12.09 million from a year ago;
analysts
expected $22.11 million.
* Nurix Therapeutics Inc's reported EPS for the quarter was
a loss
of 71 cents.
* The company reported a quarterly loss of $44.55 million.
* Nurix Therapeutics Inc shares had fallen by 3.0% this
quarter and gained 96.1% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 17.1%
in the last three months.
* In the last 30 days, there have been no negative revisions
of
earnings estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 11 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Nurix
Therapeutics Inc is $26.00
This summary was machine generated from LSEG data July 11 at
09:01 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
May. 31 2024 -0.63 -0.71 Missed
Feb. 29 2024 -0.80 -0.76 Beat
Nov. 30 2023 -0.57 -0.77 Missed
Aug. 31 2023 -0.76 -0.68 Beat